Manufacturing Expansions Amidst Supply Chain Challenges
Due to the escalating Red Sea crisis, manufacturers everywhere are reviewing their supply chains and identifying potential areas of concern. According to the British Generic Manufacturers Association, pharmaceutical manufacturers are feeling the pressure. There has been a 100% increase in shortages compared with January 2022. This is due to manufacturing difficulties, the delay of raw materials in the supply chain and unexpected demand.
As a result, pharmaceutical manufacturers are investing in factory expansions. GSK is improving its facilities to support its global manufacturing network and Boehringer Ingelheim has upgraded its plant in Koropi, with an investment of €120m (US$131m).
GSK bolsters UK manufacturing with £67m investment
British pharmaceutical manufacturer GSK is constructing new facilities and assembly lines, as well as investing £67m in improving a factory in Montrose, Scotland.
“GSK has a proud heritage of making innovative medicines in the UK. Our six UK manufacturing sites, including Montrose, are an important part of our global manufacturing network and we’re continuously investing in science, technology and skills to deliver medicines faster and more efficiently,” said Regis Simard, Head of Global Supply Chain at GSK.
Boehringer Ingelheim's pharmaceutical manufacturing expansion in Greece
German pharmaceutical manufacturer Boehringer Ingelheim is setting up a new manufacturing base in Greece, following an investment of €120m (US$131m). Founded in 1885 and family-owned, Boehringer Ingelheim has 53,000 employees working in over 130 markets. Its expansion in Greece will create 110 new jobs and increase the exports of Jardiance from Greece. Jardiance is a medication which supports those living with:
- Type 2 diabetes
- Chronic (long-term) heart failure
- Chronic kidney disease.
Greek Prime Minister Kyriakos Mitsotakis attended the opening ceremony at the Koropi site.
“I am delighted to once again visit this plant which, as we have heard, produces some of the most innovative antidiabetic medicines and to see the excellent organisation as well as the high level of expertise and professionalism of the staff,” said the Prime Minister. “I am also very pleased with the progress that the company has made.”
Mitsotakis thanked Boehringer Ingelheim for its continuous trust in Greece.
“It is a strategic goal that we as a state also embrace: to make our country a reference point for the pharmaceutical industry.”
“We have been present in Greece since 1966, and have gradually expanded our operations in the country,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors at Boehringer Ingelheim. “This expansion investment will bring some of our most innovative therapies to an increasing number of patients globally.”
******
Make sure you check out the latest edition of Manufacturing Digital and also sign up to our global conference series - Procurement & Supply Chain 2024 & Sustainability LIVE 2024
******
Manufacturing Digital is a BizClik brand